Skip Navigation

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sampson, J. R.
Right arrow Articles by Harris, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sampson, J. R.
Right arrow Articles by Harris, P. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, Vol 3, 1477-1480, Copyright © 1994 by Oxford University Press

ARTICLES

The molecular genetics of tuberous sclerosis

JR Sampson and PC Harris
Institute of Medical Genetics, University Hospital of Wales, Cardiff UK.

Tuberous sclerosis (TSC) is an autosomal dominant trait characterized by the widespread development of benign tumours classified as hamartoma, and is often associated with seizures and mental retardation. The patchy distribution and focal nature of the growths suggests that they might result from inactivation of a tumour suppressor gene by a two-hit process. Over the last 2 years, studies designed to investigate both germline and somatic TSC mutations have lent support to this hypothesis. Analysis of TSC-associated hamartomas has shown loss of heterozygosity for the regions of chromosomes 9 and 16 known to harbour TSC genes, consistent with the occurrence of somatic 'second-hit' mutations. Parallel investigations using pulse field gel electrophoresis have identified constitutional deletions representing 'first-hit' mutations at 16p13.3, leading to the rapid identification of one of the causative genes, TSC2. Intriguingly, the TSC2 product, tuberin, has an area of sequence homology with the GTPase activating protein rap1GAP, suggesting a possible mechanism for its role in regulating cellular growth.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 RadiologyHome page
N. A. Avila, A. J. Dwyer, A. Rabel, and J. Moss
Sporadic Lymphangioleiomyomatosis and Tuberous Sclerosis Complex with Lymphangioleiomyomatosis: Comparison of CT Features
Radiology, December 1, 2006; 242(1): 277 - 285.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
J. A. Shields, R. C. Eagle Jr, C. L. Shields, and B. P. Marr
Aggressive Retinal Astrocytomas in 4 Patients With Tuberous Sclerosis Complex
Arch Ophthalmol, June 1, 2005; 123(6): 856 - 863.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Govindarajan, D. J. Brat, M. Csete, W. D. Martin, E. Murad, K. Litani, C. Cohen, F. Cerimele, M. Nunnelley, B. Lefkove, et al.
Transgenic Expression of Dominant Negative Tuberin through a Strong Constitutive Promoter Results in a Tissue-specific Tuberous Sclerosis Phenotype in the Skin and Brain
J. Biol. Chem., February 18, 2005; 280(7): 5870 - 5874.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
L. Singh, Q. Gao, A. Kumar, T. Gotoh, D. E. Wazer, H. Band, L. A. Feig, and V. Band
The High-Risk Human Papillomavirus Type 16 E6 Counters the GAP Function of E6TP1 toward Small Rap G Proteins
J. Virol., December 20, 2002; 77(2): 1614 - 1620.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. Pacheco-Rodriguez, A. S. Kristof, L. A. Stevens, Y. Zhang, D. Crooks, and J. Moss
Genetics and Gene Expression in Lymphangioleiomyomatosis : Giles F. Filley Lecture
Chest, March 1, 2002; 121 (2009): 56S - 61S.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. MOSS, N. A. AVILA, P. M. BARNES, R. A. LITZENBERGER, J. BECHTLE, P. G. BROOKS, C. J. HEDIN, S. HUNSBERGER, and A. S. KRISTOF
Prevalence and Clinical Characteristics of Lymphangioleiomyomatosis (LAM) in Patients with Tuberous Sclerosis Complex
Am. J. Respir. Crit. Care Med., August 15, 2001; 164(4): 669 - 671.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Miloloza, M. Rosner, M. Nellist, D. Halley, G. Bernaschek, and M. Hengstschlager
The TSC1 gene product, hamartin, negatively regulates cell proliferation
Hum. Mol. Genet., July 22, 2000; 9(12): 1721 - 1727.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Nellist, M. A. van Slegtenhorst, M. Goedbloed, A. M. W. van den Ouweland, D. J. J. Halley, and P. van der Sluijs
Characterization of the Cytosolic Tuberin-Hamartin Complex. TUBERIN IS A CYTOSOLIC CHAPERONE FOR HAMARTIN
J. Biol. Chem., December 10, 1999; 274(50): 35647 - 35652.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Soucek, R. S. Yeung, and M. Hengstschlager
Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2
PNAS, December 22, 1998; 95(26): 15653 - 15658.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
R. E. Schnur
Tuberous Sclerosis: The Persistent Challenge of Clinical Diagnosis
Arch Dermatol, December 1, 1995; 131(12): 1460 - 1462.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.